Needham & Company LLC Has Lowered Expectations for Liquidia (NASDAQ:LQDA) Stock Price

Posted by Brenda Bartman on Oct 1st, 2026

Liquidia (NASDAQ:LQDA – Get Free Report) had its price objective reduced by analysts at Needham & Company LLC from $110.00 to $72.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 137.94% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Wells Fargo & Company increased their price objective on shares of Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Zacks Research downgraded Liquidia from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 22nd. Lifesci Capital lowered Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price objective for the company. in a research note on Wednesday, August 12th. Oppenheimer set a $75.00 price objective on Liquidia in a report on Friday, June 5th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $106.00 target price on shares of Liquidia in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $94.92.

View Our Latest Stock Report on LQDA

Liquidia Price Performance

Shares of LQDA opened at $30.26 on Thursday. The firm has a market capitalization of $2.71 billion, a PE ratio of 22.09 and a beta of 0.53. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The company’s fifty day moving average price is $74.00 and its 200-day moving average price is $62.32. Liquidia has a 1-year low of $21.35 and a 1-year high of $93.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the prior year, the company earned ($0.49) EPS. Liquidia’s quarterly revenue was up 1842.1% on a year-over-year basis. On average, equities research analysts predict that Liquidia will post 2.57 EPS for the current year.

Insider Buying and Selling

In other Liquidia news, Director Stephen Bloch sold 100,000 shares of the stock in a transaction that occurred on Thursday, July 23rd. The stock was sold at an average price of $89.48, for a total transaction of $8,948,000.00. Following the transaction, the director owned 501,477 shares in the company, valued at approximately $44,872,161.96. This represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Katherine Rielly-Gauvin sold 36,789 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $74.99, for a total value of $2,758,807.11. Following the transaction, the director owned 44,637 shares in the company, valued at $3,347,328.63. This represents a 45.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 597,519 shares of company stock worth $46,091,764 in the last ninety days. 25.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently added to or reduced their stakes in LQDA. WINTON GROUP Ltd purchased a new stake in Liquidia in the 2nd quarter worth $335,000. Arizona State Retirement System lifted its holdings in Liquidia by 5.4% during the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after purchasing an additional 900 shares in the last quarter. Nykredit A S purchased a new position in Liquidia during the second quarter valued at $177,000. Corient Private Wealth LP acquired a new stake in shares of Liquidia in the second quarter valued at about $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Liquidia in the second quarter valued at about $1,236,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: YUTREPIA adoption is generating substantial revenue, profits and cash flow, providing Liquidia with an operating foundation for continued growth. The company also plans to appeal the ruling and pursue a potential label modification. Liquidia: Bullish On Their Growth Potential Despite YUTREPIA’s Legal Tail Risk
Neutral Sentiment: The Delaware District Court found two of the six asserted claims in United Therapeutics’ ’327 patent valid and infringed, while ruling that the remaining claims were invalid. The companies must submit proposed remedies within one week, leaving the precise commercial impact unresolved. Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
Negative Sentiment: The adverse patent decision threatens YUTREPIA’s commercial outlook. Potential remedies range from removing the pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication to restricting the product’s broader market availability; United Therapeutics is seeking injunctive relief. Liquidia has said it will appeal, but the company cannot yet estimate its potential financial exposure. Liquidia Slumps After US Court Rules for United Therapeutics in Patent Fight
Negative Sentiment: The litigation news triggered repeated LULD and news-pending trading halts as investors reassessed YUTREPIA’s revenue potential. The sharp selloff reflects the risk that the product’s rapid growth—revenue rose more than 1,800% year over year in the latest reported quarter—could be curtailed by the patent remedy.

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).